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S UMM A R Y
S E T T I NG : Thirteen districts in Eastern Cape (EC),
KwaZulu-Natal (KZN) and Western Cape (WC) Prov-
inces, South Africa.
OB J E C T I V E : To pilot a methodology for describing and
visualising healthcare journeys among drug-resistant
tuberculosis (DR-TB) patients using routine laboratory
records.
DE S I GN : Laboratory records were obtained for 195
patients with laboratory-detected rifampicin-resistant
TB (RR-TB) during July–September 2016. Health
facility visits identified from these data were plotted to
visualise patient healthcare journeys. Data were verified
by facility visits.
R E SU LT S : In the 9 months after the index RR-TB
sample was collected, patients visited a mean of 2.3
health facilities (95% CI 2.1–2.6), with 9% visiting 4
facilities. The median distance travelled by patients from
rural areas (116 km, interquartile range [IQR] 50–290)
was greater than for urban patients (51 km, IQR 9–140).
A median of 21% of patient’s time was spent under the
care of primary healthcare facilities: this was respective-
ly 6%, 37% and 39% in KZN, EC and WC. Journey
patterns were generally similar within districts. Some
reflected a semi-centralised model of care where patients
were referred to regional hospitals; other journeys
showed greater involvement of primary care.
CONC LU S I ON : Routine laboratory data can be used to
explore DR-TB patient healthcare journeys and show
how the use of healthcare services for DR-TB varies in
different settings.
K E Y WORD S : tuberculosis; MDR-TB; mapping; GIS;
health systems; routine data; patient-focused
SOUTH AFRICA CONTRIBUTES 10% of the total
global burden of notified drug-resistant tuberculosis
(DR-TB, defined as resistance to at least rifampicin,
and including multi- and extensively DR-TB), with
16 733 patients diagnosed in 2017.1 While a large
number of patients are diagnosed nationally, only
64% were estimated to have started second-line
treatment in 2013.2 Treatment outcomes are poor,
with only 55% treatment success among those
starting treatment in 2015.1
In response to the large burden of DR-TB in South
Africa, a national policy to decentralise DR-TB
services was launched in 2011.3 Both the conven-
tional 18–24 month and the shortened 9–12 month
DR-TB regimens are arduous and associated with
significant adverse events.4,5 Patients taking these
regimens require monthly monitoring with labora-
tory tests to identify drug toxicities and determine
treatment response.5 Hospital admissions are also
burdensome for patients and providers, and efforts
to reduce this burden through community-based
models of care have been described.6–10 Decentral-
ised care has been reported to achieve similar or
better outcomes than centralised treatment pro-
grammes11,12 while being more acceptable to pa-
tients and reducing provider costs.13,14 Ambulatory-
based models of care are recommended by the World
Health Organization (WHO).5
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Since 2011, different models of decentralised DR-
TB care have emerged across South Africa based on
different interpretations of the policy and the varying
contexts within which care is delivered.15,16 Pub-
lished analyses of patient pathways have recently
highlighted the mismatch between health service
provision and the preferences of drug-susceptible
TB patients seeking care.17,18 Examining where DR-
TB patients access care and tracing their journeys
between health facilities may help us understand
better variations in the implementation of decentral-
ised care in different settings. As part of a broader
health systems research project investigating how
health systems may be optimised to deliver high-
quality, patient-centred, decentralised care for DR-
TB, we aimed to pilot a methodology that utilises
routine laboratory data to describe and visualise
patient pathways through healthcare services.
METHODS
This was a descriptive pilot study aiming to assess
whether routine laboratory data could be used to
construct DR-TB patient healthcare journeys in South
Africa. The pilot study was conducted in 13 districts
across three of the nine South African provinces:
Eastern Cape (EC), KwaZulu-Natal (KZN) and
Western Cape (WC). These were chosen based on
key informant interviews with local and national TB
programme staff (unpublished), suggesting variations
in the implementation of decentralised care, as well as
to include both rural and urban areas.
Participants
Patients with a new diagnosis of rifampicin-resistant
tuberculosis (RR-TB) where the diagnostic specimen
was collected during July–September 2016 at a health
facility in one of the study districts were eligible. New
diagnoses were defined as a diagnostic RR-TB result
with no previous such results during the preceding 6
months. A random sample of 15 patients was selected
(using a random number generator) from a list of
patients generated from the laboratory data for each
district. This sample size was chosen for pragmatic
reasons in order to be able to verify the patient
journeys derived from laboratory data. Patients were
excluded if discordant results indicated drug-suscep-
tible TB, or if no subsequent laboratory records could
be matched to the patient (i.e., no health care journey
could be constructed). In these circumstances, re-
placement patients were randomly selected.
Data sources
All laboratory data were obtained from the National
Health Laboratory Service (NHLS), which provides
laboratory services for government health services,
including all TB services, in South Africa.19 Along with
the list of all RR-TB patients diagnosed between July
and September 2016 from the 13 districts, raw data
comprising all laboratory records linked to the ran-
domly selected patients during a 9-month follow-up
period, beginning when the index RR-TB specimen was
collected, were obtained from the NHLS central data
warehouse. These laboratory data provided informa-
tion on all laboratory testing, including TB-related
testing, adverse event monitoring and human immuno-
deficiency virus (HIV) related tests. As there is no
unique patient identifier consistently captured at health-
care visits, an automated linking algorithm was applied
by the NHLS to identify different healthcare visits by
the same patient. To identify specimens missed by the
linking algorithm, the online NHLS database was then
manually searched for the same follow-up period using
name and date of birth variations, hospital folder
numbers and facility names.
Facility names were extracted from laboratory
records, along with facility type and location. Facility
type was categorised as either: primary care; secondary
hospital (district and regional hospitals, including those
containing DR-TB units); and tertiary hospital (also
including DR-TB units); TB hospital; or TB Centre of
Excellence hospital (one of which is designated in each
province). In addition toNHLS geographic coordinates
for health facilities, the South African District Health
Management Information System (DHMIS) and the
healthsites.org.za resourcewere used to confirm facility
location. If no coordinates could be found, we collected
new spatial data from online sources.
Rural/urban categorisation was obtained from two
different sources.20,21 In order to verify patient care
journeys, we visited all health facilities identified by
laboratory records, searched for and, if located,
reviewed medical records for all participants. We
then compared these to healthcare journeys con-
structed using laboratory records, to detect discor-
dance, or missing visits.
Data analysis
Unique combinations of facility name and collection
date were extracted from laboratory data, and placed
in chronological order for each patient. Records of
different health facilities at which samples were
collected, on different days, formed patient health-
care journeys. We then described and visualised these
journeys.
Spatial data were analysed and maps produced in
ArcGIS v10.5.1 (ESRI, Redlands, CA, USA). Descrip-
tive statistics were analysed in Stata v13.1 (StataCorp,
College Station, TX, USA). Patient time bar charts
were produced using Excel 2016 (Microsoft, Seattle,
WA, USA). We assumed that a health facility was
responsible for patient care until the patient provided a
laboratory specimen at a new health facility. We
assumed that patients remained in the care of the last
recorded health facility for 14 days, or until the end of
the follow-up period, whichever was earlier.
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Ethical approval
Ethical approval for the study was provided by
the University of Cape Town, Cape Town, South
Africa (350/2016), and the London School of
Hygiene & Tropical Medicine, London, UK
(11680); research approval was obtained in each
province (EC_2016RP30_232, KZ_2016RP51_466,
WC_2016RP45_978).
RESULTS
Characteristics of study participants
The study sample included 195 participants from 13
districts in three provinces (Figure 1). Patients were
followed for a median of 248 days (interquartile
range [IQR] 176–267) within the 9-month period,
based on our definition of remaining in care. Among
the sample, 120 (61%) were male, and the median
age was 35 years (IQR 28–44; Table).
Validation of laboratory data with clinical record review
Clinical records were located for 76% of patients
(149/195). All facility visits identified using labora-
tory data for these patients were confirmed in clinical
records. Additional facility visits were identified in
facility records for 16% (24/149) of these patients.
For the majority of these patients, this was an
additional single health facility visit, predominantly
unrelated to their TB care.
Healthcare visits and distance travelled
Patients visited a mean of 2.3 different health
facilities (95% confidence interval [CI] 2.1–2.6),
with a mean of 12.2 health facility visits recorded
per patient (95%CI 11.7–12.7) over the 9-month
follow-up period. Results from univariate analysis by
sub-group are given in the Table. While the mean
number of unique facilities visited varied little by the
factors assessed, the proportion of patients who
visited four or more facilities varied considerably;
more patients from KZN visited at least four
facilities.
Of the 25 patients who remained at a single facility
for all recorded health facility visits, 13 were
diagnosed in WC. Patients from WC also switched
facilities less than those from the other two provinces.
Healthcare visits were similar across age, sex and
multi/extensively DR-TB subgroups. As the treatment
initiation date cannot be inferred from laboratory
data alone, it is unclear whether different health
facilities were visited as part of the diagnostic process,
initiation of treatment or for treatment monitoring.
Figure 1 Diagram illustrating the eligibility, sampling and exclusion process. NHLS ¼ National
Health Laboratory Service; RR-TB¼ rifampicin-resistant tuberculosis; DS-TB¼drug-susceptible TB.
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The median cumulative distance travelled be-
tween facilities over the follow-up period was 66
km (IQR 15–207). The median distance travelled
was greater for patients from rural areas (116 km,
IQR 50–290) than for those from urban areas (51
km, IQR 9–140). Figure 2 shows these data
disaggregated by province. The difference in dis-
tance travelled between rural and urban patients was
Table Characteristics of participants and univariate results
n
Number of unique
facilities visited*
Number of transfers
between facilities*
Total distance
travelled, km
Proportion of time spent
in primary care, %
Mean (95% CI)
4
% Mean (95% CI)
4
% Median [IQR] Median [IQR]
All 195 2.4 (2.2–2.6) 9 2.3 (2.1–2.6) 21 66 [15–207] 21 [2–60]
Sex
Female 75 2.4 (2.1–2.8) 9 2.2 (1.9–2.5) 15 77 [29–243] 20 [0–55]
Male 120 2.4 (2.1–2.6) 8 2.4 (2.2–2.7) 24 64 [9–176] 23 [6–69]
Age, years
0–19 10 2.5 (1.6–3.7) 10 2.2 (1.4–3.3) 20 104 [51–290] 6 [0–34]
20–29 46 2.5 (2.1–3) 20 2.5 (2.1–3) 26 98 [23–293] 20 [4–66]
30–39 61 2.3 (1.9–2.7) 5 2.3 (2–2.8) 18 62 [5–206] 18 [1–60]
40–49 51 2.4 (2–2.8) 6 2.3 (1.9–2.8) 22 74 [15–206] 31 [8–72]
50 27 2.3 (1.8–3) 4 2.1 (1.6–2.7) 15 42 [17–110] 23 [0–48]
Province
Eastern Cape 60 2.4 (2.1–2.9) 8 2.8 (2.4–3.2) 28 76 [19–266] 37 [17–70]
KwaZulu-Natal 75 2.5 (2.1–2.9) 11 2.4 (2.1–2.8) 21 92 [47–216] 6 [0–19]
Western Cape 60 2.2 (1.8–2.6) 7 1.8 (1.4–2.1) 12 36 [2–172] 39 [16–91]
Place of residence
Urban 121 2.4 (2.1–2.7) 7 2.4 (2.2–2.7) 21 51 [9–140] 23 [7–60]
Rural 74 2.4 (2–2.8) 11 2.2 (1.9–2.5) 19 116 [50–290] 11 [0–60]
Type of resistance
First-line drug† 124 2.3 (2.1–2.6) 7 2.2 (2–2.5) 19 81 [12–205] 22 [2–60]
Second-line drug‡ 48 2.5 (2.1–3) 13 2.7 (2.3–3.2) 27 76 [18–220] 22 [4–53]
Missing 23 2.3 (1.7–3) 9 2 (1.5–2.7) 17 33 [10–60] 14 [0–85]
* Poisson distributions used to calculate means and CIs for count variables.
† Rifampicin, isoniazid, pyrazinamide, ethambutol.
‡ Fluoroquinolones, aminoglycosides, bedaquiline, delamanid, linezolid, ethionamide, cycloserine/terizidone, clofazimine, para-aminosalicylic acid.
CI¼ confidence interval; IQR¼ interquartile range.
Figure 2 Distances travelled by patients from urban and rural areas, disaggregated by province, with box and whisker plots
denominating the median (central bar), interquartile range (box ends), and adjacent values (whisker, largest/smallest values within 1.5
times interquartile range of the upper and lower quartiles). Each point represents a single patient. The horizontal scale is broken and
condensed at right to show outliers.
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more pronounced in EC and in WC than in KZN.
Although some patients travelled extraordinary
distances during the follow-up period (max: 2,598
km), chart review revealed that these patients had
been transferred across provinces.
Mapping patient health care journeys
Figures representing individual patient journeys
(Figures 3–5) show how patterns of care emerge
when DR-TB patient healthcare journeys are viewed
together. In EC, patients from rural areas travelled to
and from two centralised DR-TB units to obtain
care—a quasi-centralised model. In KZN a ‘hub and
spoke’ pattern emerged, with most patient journeys
focused around regional ‘hub’ hospitals, some pa-
tients referred to centralised units, and some decen-
tralised to lower level hospitals or clinics. In WC,
patient journeys in urban areas reflected largely
decentralised care utilising primary care facilities,
compared to more rural areas where patients trav-
elled to TB hospitals.
Figure 3 Patients’ health care journeys in Eastern Cape Province. A) Detail of patients’ journeys in Buffalo City Metro district (Port
Elizabeth). B) Detail of patients’ journeys in Oliver Reginald Tambo District. In all maps, individual patients are represented by
differently coloured/styled lines, with arrows indicating the direction of travel; those who were diagnosed and treated at a single
facility are represented by blue stars instead of coloured lines (‘stationary patients’ in the legend). COE hospital names are in capitals.
Health facilities that are most frequently visited by patients are labelled by name. TB¼ tuberculosis; COE¼ Centre of Excellence.
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Time spent at lower levels of care
The median proportion of time in care that was spent
under primary care was 21% (IQR 2–60). Patients
from KZN spent a median of 6% of the duration of
their healthcare journey under primary care (IQR 0–
19), lower than either EC or WC patients (median,
37%; IQR 17–70 and median, 39%; IQR 16–91,
respectively).
Time spent in different levels of care is charted in
Figure 6. In WC, patients were mostly diagnosed and
treated at primary care facilities, with a subgroup of
patients referred to TB hospitals and then back to
primary care. In EC, most patients also started their
healthcare journeys in primary care, however there
was greater use of centralised units. Journeys of
patients from KZN demonstrated low utilisation of
primary care facilities, but greater use of TB hospitals
in each region.
DISCUSSION
This pilot study demonstrates how routine laboratory
data can be used to describe and visualise DR-TB
patient journeys through the healthcare system in
South Africa. In this setting, decentralisation of DR-
TB care aims to provide care at lower levels of the
health system, both to improve treatment access and
to deliver patient-centred care.3 The patient journeys
described here can be used to identify differences in
patterns of care in order to explore variations in the
implementation of decentralised care and generate
hypotheses regarding the health system or patient
features which may impact implementation. This
methodology is comparable to that of Clouse et al.,
who used centrally collated NHLS laboratory data to
map HIV patient encounters with the health sys-
tem.22 As DR-TB treatment generates comparably
more laboratory data, we are able to construct a more
Figure 4 Patients’ health care journeys in KwaZulu-Natal Province.A) Detail of patients’ journeys
in Ethekwini District (Durban). B) Detail of patients’ journeys in Uthungulu District. COE hospital
names are in capitals. TB¼ tuberculosis; COE¼ Centre of Excellence.
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granular picture of encounters over a longer period.
In Thailand, mapping has been used to understand
DR-TB patient journeys, albeit on a much smaller
scale and focused on infectious spread during the pre-
treatment period.23 In comparison, we have focused
on patient journeys to obtain an understanding of
patterns of care.
While this was a pilot study and the sample was
not intended to be representative, the quantitative
results suggest that patient journeys may differ
according to the province in which the patient lives,
whereas results were similar across other subgroups.
This could reflect different models of care in each
province, or other provincial-level differences. For
example, these data suggest that DR-TB care has
been decentralised to primary healthcare level in WC
(fewer facilities, fewer switches between facilities
and more time spent in primary care), which is
consistent with the .400 decentralised facilities
reported there.15,16 Conversely, rural patients trav-
elled larger distances in this study. Challenges in
access to care in rural areas in South Africa are well
documented, consistent with our findings.24,25
More meaningful insights were derived from visu-
Figure 5 Patients’ health care journeys inWestern Cape Province.A) Detail of patients’ journeys in City of Cape Town district. B)Detail
of patients’ journeys in Eden District. COE hospital names are in capitals. TB¼ tuberculosis; COE¼ Centre of Excellence.
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alisations of individual patient journeys. There were
clear differences in the implementation of decentral-
ised DR-TB care between provinces, identifiable as
different patterns emerging in maps of patient health
care journeys. The maps of patient journeys in the WC
showing highly decentralised care within clinics in the
City of Cape Town compared with the long distances
travelled by rural patients suggest that models of care
differ between the City of Cape Town and rural
districts. In EC, the maps showed patients being
referred back and forth between peripheral and
centralised sites, a reality corroborated by analysis of
patient journeys over time which showed periods of
time spent in primary care facilities, interspersed with
care in TB Centres of Excellence.
Our methodology has several limitations that
would be apparent even if the methodology were to
be applied on a larger scale using more representative
data. First, the method requires linkage of laboratory
tests to the same individual across episodes of care in
different health facilities. We achieved this using
manual matching. However, there are a variety of
algorithmic techniques that could be utilised.26 Our
method also requires accurate spatial data for health
facilities. In the NHLS data, only half the named
facilities had useable geographic coordinates. The
introduction of unique identifiers and improvements
to the recording of spatial data by the NHLS, which
are both underway, will make NHLS data an
increasingly valuable tool for programmatic analysis
of patient journeys. Second, a visit would only be
recorded on the laboratory information system if a
specimen was submitted; 16% of facility visits were
missed based on the clinical record review, predom-
inantly as there were no laboratory specimens taken.
Third, there is no reliable way to identify from
laboratory metadata whether a patient is admitted or
treated as an outpatient, or what the treatment
outcome was. As patient home addresses are not
reliably captured by the laboratory database, we are
unable to determine how close to home a patient
received care. Our analysis of time spent in different
levels of care is also limited by approximating the
date on which care was transferred. Finally, since we
excluded participants who had only one laboratory
result, we did not capture care for patients who died
early or were lost to follow-up.
The methodology and results of this study should
be interpreted in the context of a range of factors,
including geography, health system capacity, popula-
tion density and DR-TB burden. Given the wide
variation in these factors,25,27 implementation of
decentralised DR-TB care in South Africa is likely to
vary and local adaptation to the needs of patients and
communities in different areas would be appropriate.
These contextualising factors have also been recog-
nised in related research (for example, patient
pathway analysis) in South Africa and international-
ly.18
Routine laboratory records provide an important
source of data for research into health systems and
responses to the TB epidemic. This study pilots a
methodology for the use of routine laboratory records
to reconstruct DR-TB patient health care journeys,
and the results highlight different patterns emerging
from the implementation of decentralised care for
DR-TB in selected districts in South Africa. These
patterns provide a starting point for understanding
the varying responses of the health system to
implementation of a policy of decentralised care
and the complex healthcare journeys for some
patients.
Figure 6 Bar chart of patient journeys during the follow-up
period, showing consecutive changes in level of care, by province.
Each patient is represented by one horizontal bar, with the date
the diagnostic sample was taken for each patient represented as
day 0. Orange: primary health care facilities. Grey: secondary
hospitals. Yellow: tertiary hospitals. Blue: centralised DR-TB units.
Green: TB COE hospitals. DR-TB ¼ drug-resistant TB; COE ¼
Centre of Excellence; TB¼ tuberculosis.
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R E´ S U M E´
CONT EX T E : Treize districts des provinces du Cap Est
(EC), du KwaZulu-Natal (KZN) et du Cap Ouest (WC),
Afrique du Sud.
OB J E C T I F : Piloter une me´thode de description et de
visualisation du parcours de soins des patients atteints de
tuberculose pharmacore´sistante (DR-TB) graˆce a` des
dossiers de laboratoire de routine.
S CH E´MA : Les dossiers des laboratoires ont e´te´ obtenus
pour 195 patients ayant eu une TB re´sistante a` la
rifampicine (RR-TB), de´tecte´e par le laboratoire de
juillet a` septembre 2016. Les consultations identifie´es a`
partir de ces donne´es ont e´te´ localise´es afin de visualiser
le parcours de soins. Les donne´es ont e´te´ ve´rifie´es graˆce a`
des visites dans les structures de soins.
R E´ S U LTAT S : Au cours des 9 mois suivant le recueil de
l’e´chantillon RR-TB index, les patients se sont rendus
dans une moyenne de 2,3 structures de sante´ (IC95%
2,1–2,6), et 9% sont alle´s dans 4 structures. La
distance me´diane couverte par les patients des zones
rurales (116 km, intervalle interquartile [IQR] 50–290) a
e´te´ plus e´leve´ que pour les patients urbains (51 km, IQR
9–140). Une me´diane de 21% du temps des patients a e´te´
passe´e dans des structures de soins de sante´
primaires ; 6%, 37% et 39% dans les provinces du
KZN, du EC et du WC, respectivement. Les profils de
parcours ont e´te´ ge´ne´ralement similaires dans les
diffe´rents districts. Dans certains cas, le mode`le de
soins e´tait semi centralise´ et les patients ont e´te´ re´fe´re´s a`
des hoˆpitaux re´gionaux ; d’autres parcours ont mis en
e´vidence une plus grande implication des soins de sante´
primaires.
CONC LU S I ON : Les donne´es de laboratoire de routine
peuvent eˆtre utilise´es pour explorer les parcours de soins
de patients DR-TB et illustrer la fac¸on dont l’utilisation
des services de soins de sante´ de la DR-TB varie en
fonction du contexte.
R E S UM E N
MA R C O D E R E F E R E N C I A: Trece distritos en las
provincias del Cabo Oriental (EC), KwaZulu-Natal
(KZN) y el Cabo Occidental (WC) en Sura´frica.
OB J E T I VO: Realizar el ensayo preliminar de un me´todo
para describir y visualizar el itinerario asistencial de los
pacientes con tuberculosis farmacorresistente (DR-TB),
a partir de los registros corrientes de laboratorio.
M E´ TODO: Se obtuvieron los registros de laboratorio de
195 pacientes con TB resistente a rifampicina (RR-TB)
detectada en el laboratorio de julio a septiembre del
2016. Se trazaron en gra´ficos las consultas al
establecimiento de salud a partir de estos datos, con el
fin de visualizar los itinerarios asistenciales de los
pacientes. Los datos se verificaron con las citas al
centro asistencial.
R E SU LTADOS: En los 9 meses posteriores a la fecha de
recogida de la muestra inicial RR-TB, los pacientes
acudieron en promedio a 2,3 centros de atencio´n
(IC95% 2,1–2,6) y 9% consultaron cuatro centros o
ma´s. La mediana de la distancia recorrida por los
pacientes de zonas rurales (116 km; amplitud
intercuartı´lica [IQR] 50–290) fue mayor que la
distancia recorrida por los pacientes urbanos (51 km;
AIC 9–140 km). En promedio, 21% del tiempo de
atencio´n de los pacientes transcurrio´ en establecimientos
de atencio´n primaria; esta proporcio´n fue 6% en KZN,
37% en el EC y 39% en el WC. El perfil de los itinerarios
fue equivalente en cada distrito. En algunos casos se
observo´ un modelo de atencio´n semicentralizada, en el
cual los pacientes se remitı´an a hospitales regionales;
otros itinerarios revelaron una mayor participacio´n de la
atencio´n primaria.
CONC LU S I O´ N: Los datos corrientes del laboratorio se
pueden utilizar con el fin de evaluar los itinerarios
asistenciales de los pacientes con DR-TB y reflejan las
diferencias en la utilizacio´n de los servicios de salud por
este tipo de TB en los diversos entornos.
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